Motexafin lutetium

Drug Profile

Motexafin lutetium

Alternative Names: Antrin®; FP FP1; Lu-Tex; Lu-Tex/OPTRIN; Lutetium texaphyrin; Lutrin®; Optrin™; PCI 0123

Latest Information Update: 09 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacyclics
  • Class Antineoplastics; Oxidants; Texaphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Atherosclerosis; Breast cancer; Cervical intraepithelial neoplasia; Coronary artery restenosis; Peripheral arterial disorders; Prostate cancer; Vascular restenosis

Most Recent Events

  • 28 Mar 2006 Motexafin lutetium is available for licensing worldwide (http://www.pharmacyclics.com)
  • 15 Nov 2004 Data presented at the American Heart Association Scientific Sessions (AHA-2004) have been added to the Ischaemic Heart Disease pharmacodynamics section
  • 12 Oct 2004 Data presented at the 16th Annual Transcatheter Cardiovascular Therapeutics conference (TCT-2004) have been added to the Ischaemic Heart Disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top